Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–85.
Bhatia S. Genetics of anthracycline cardiomyopathy in cancer survivors. JACC: CardioOncology. 2020;2(4):539–52.
PubMed PubMed Central Google Scholar
Basak D, Gamez D, Deb S. SGLT2 inhibitors as potential anticancer agents. Biomedicines. 2023;11(7):1867.
Article CAS PubMed PubMed Central Google Scholar
Wu W, Wang Y, Xie J, Fan S. Empagliflozin: a potential anticancer drug. Discov Oncol. 2023;14(1):127.
Article PubMed PubMed Central Google Scholar
Armenian SH, Hudson MM, Mulder RL, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015;16(3):e123–36.
Article PubMed PubMed Central Google Scholar
Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J. 2022;43(41):4229–361.
Henriksen PA, Rankin S, Lang NN. Cardioprotection in patients at high risk of anthracycline-induced cardiotoxicity. JACC: CardioOncology. 2023;5(3):292–7.
PubMed PubMed Central Google Scholar
Chang H-M, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular complications of cancer therapy. J Am Coll Cardiol. 2017;70(20):2536–51.
Article PubMed PubMed Central Google Scholar
Chang H-M, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. J Am Coll Cardiol. 2017;70(20):2536–51.
Article PubMed PubMed Central Google Scholar
Henriksen PA, Rankin S, Lang NN. Cardioprotection in patients at high risk of anthracycline-induced cardiotoxicity: JACC: CardioOncology Primer. JACC: CardioOncology. 2023;5(3):292–7.
PubMed PubMed Central Google Scholar
Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18(11):1639–42.
Jirkovský E, Jirkovská A, Bavlovič-Piskáčková H, et al. Clinically translatable prevention of anthracycline cardiotoxicity by dexrazoxane is mediated by topoisomerase II beta and not metal chelation. Circ Heart Fail. 2021;14(11):e008209.
Baldassarre LA, Ganatra S, Lopez-Mattei J, et al. Advances in multimodality imaging in cardio-oncology: JACC state-of-the-art review. J Am Coll Cardiol. 2022;80(16):1560–78.
Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2021;77(3):243–55.
Article CAS PubMed Google Scholar
Yurista SR, Chong C-R, Badimon JJ, et al. Therapeutic potential of ketone bodies for patients with cardiovascular disease. J Am Coll Cardiol. 2021;77(13):1660–9.
Article CAS PubMed Google Scholar
Usman MS, Siddiqi TJ, Anker SD, et al. Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations. J Am Coll Cardiol. 2023;81(25):2377–87.
Article CAS PubMed Google Scholar
Dutka M, Bobiński R, Francuz T, et al. SGLT-2 inhibitors in cancer treatment-mechanisms of action and emerging new perspectives. Cancers (Basel). 2022;14(23). https://doi.org/10.3390/cancers14235811.
Sabatino J, De Rosa S, Tammè L, et al. Empagliflozin prevents doxorubicin-induced myocardial dysfunction. Cardiovasc Diabetol. 2020;19(1):66.
Article CAS PubMed PubMed Central Google Scholar
Faggiano A, Gherbesi E, Cardinale D, Vicenzi M, Carugo S. SGLT2-i prevent left ventricular dysfunction induced by anthracycline in mouse model: a systematic-review and meta-analysis. Vasc Pharmacol. 2023;150:107171.
Oh CM, Cho S, Jang JY, et al. Cardioprotective potential of an SGLT2 inhibitor against doxorubicin-induced heart failure. Korean Circ J. 2019;49(12):1183–95.
Article CAS PubMed PubMed Central Google Scholar
Barış VÖ, Dinçsoy AB, Gedikli E, et al. Empagliflozin significantly prevents the doxorubicin-induced acute cardiotoxicity via non-antioxidant pathways. Cardiovasc Toxicol. 2021;21(9):747–58.
Quagliariello V, De Laurentiis M, Rea D, et al. SGLT2 inhibitor dapagliflozin against anthracycline and trastuzumab-induced cardiotoxicity: the role of MYD88, NLRP3, Leukotrienes/Interleukin 6 axis and mTORC1 /Fox01/3a mediated apoptosis. Eur Heart J. 2020;41(Supplement_2). https://doi.org/10.1093/ehjci/ehaa946.3253.
Scafoglio C, Hirayama BA, Kepe V, et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci. 2015;112(30):E4111–E9.
Article CAS PubMed PubMed Central Google Scholar
Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–61.
Article CAS PubMed Google Scholar
Giangiacomi F, Faggiano A, Cardinale D, et al. Case report: Sodium-glucose cotransporter 2 inhibitors induce left ventricular reverse remodeling in anthracycline-related cardiac dysfunction—a case series. Front Cardiovasc Med. 2023;10. https://doi.org/10.3389/fcvm.2023.1250185.
Gongora CA, Drobni ZD, Silva TQAC, et al. Sodium-glucose co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines. JACC: Heart Failure. 2022;10(8):559–67.
McGovern AP, Hogg M, Shields BM, et al. Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Res Care. 2020;8(1):e001238.
Article PubMed PubMed Central Google Scholar
Abdel-Qadir H, Carrasco R, Austin PC, et al. The association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with cancer. JACC: CardioOncology. 2023;5(3):318–28.
PubMed PubMed Central Google Scholar
Chiang C-H, Chiang C-H, Chiang C-H, et al. Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer. Heart. 2023;109(6):470–7.
Avula V, Sharma G, Kosiborod MN, et al. SGLT2 inhibitor use and risk of clinical events in patients with cancer therapy–related cardiac dysfunction. JACC: Heart Failure. 2024;12(1):67–78.
Perelman MG, Brzezinski RY, Waissengrin B, et al. Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors. Cardio-Oncology. 2024;10(1):2.
留言 (0)